Vivere Life Limited
UK-based personalized health and longevity startup offering AI-powered gut microbiome testing and NAD+ injection pens.
Website: https://www.viverelife.co.uk/
Cover Block
Open sources
| Attribute | Detail |
|---|---|
| Name | Vivere Life Limited (trading as Vivere) |
| Tagline | UK-based personalized health and longevity startup offering AI-powered gut microbiome testing and NAD+ injection pens. |
| Headquarters | Nottingham, United Kingdom |
| Founded | 2024 |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
Links
Open sources
- Website: https://www.viverelife.co.uk/
- LinkedIn: https://www.linkedin.com/company/vivere-life/
- Companies House: https://find-and-update.company-information.service.gov.uk/company/15899819
- Trustpilot: https://uk.trustpilot.com/review/viverelife.co.uk
What an Investor Needs First
Open sources Vivere Life Limited is a newly formed UK-based healthtech startup that has quickly assembled a direct-to-consumer offering for personalized longevity, combining high-resolution gut microbiome testing with pharmaceutical-grade NAD+ therapy. The company's pitch to investors rests on its integrated approach to a premium wellness segment, bundling advanced diagnostics with a recurring consumable product, though its early stage and lack of disclosed capital or founding team require careful due diligence.
Founded in August 2024, the company has moved from incorporation to a live e-commerce platform within a short timeframe [Companies House]. Its core product is an at-home gut microbiome test kit that uses shotgun metagenomic sequencing, a method that provides more granular data than many consumer-grade alternatives, paired with an AI-powered dashboard for personalized nutrition and lifestyle recommendations [viverelife.co.uk]. This diagnostic service is complemented by the sale of NAD+ injection pens, creating a potential dual revenue stream from one-time testing and recurring refill kits.
The founding team's background is not publicly documented; the only named officer is Paul Cartwright, listed as the Data Protection Officer [viverelife.co.uk]. No external funding rounds, investors, or valuation have been disclosed, positioning Vivere as a bootstrapped or privately financed venture in its earliest commercial phase. The business model is strictly direct-to-consumer, with services currently restricted to UK residents aged 18 and over [viverelife.co.uk].
Over the next 12-18 months, key monitors will be the company's ability to translate its premium pricing,the gut test kit retails at £263.99 on promotion,into sustainable customer acquisition and repeat purchase rates, particularly for its NAD+ refills [viverelife.co.uk]. Validation of its AI recommendation engine and any moves to secure clinical or research partnerships would signal progression beyond a pure e-commerce play. For investors, the next substantive step is likely a seed round to fund customer growth and operational scaling, which would also bring the founding team and their track record into clearer view. Partially corroborated -- Core product claims and corporate status are confirmed by primary sources; team and funding details are absent.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
Inside the Company
Open sources
Vivere Life Limited is a private UK company that began formal operations in August 2024, positioning itself in the premium consumer wellness space with a focus on gut health and longevity. The company was incorporated on 15 August 2024 under company number 15899819, with its registered office in Nottingham and a listed business activity of "Other human health activities" [Companies House]. Its public-facing brand, Vivere, markets itself as "the UK’s leader in gut testing, NAD+ therapy & biohacking" directly to consumers [viverelife.co.uk].
Key milestones since incorporation appear centered on product development and digital presence. The company established its direct-to-consumer e-commerce platform, launching its core offerings of an at-home gut microbiome test kit and a pharmaceutical-grade NAD+ injection pen. Website updates logged in late August 2026 indicate recent iterations to product packaging, pricing, and scientific framing for the gut test [PERPLEXITY SONAR PRO BRIEF]. A Trustpilot profile for customer reviews was active by at least February 2026, providing a channel for public feedback on the consumer experience [Trustpilot, February 2026].
The operational footprint remains focused on the UK. Services are explicitly restricted to users aged 18 and over with a UK shipping address, confirming a deliberate geographic focus for its initial go-to-market strategy [PERPLEXITY SONAR PRO BRIEF]. Public records list Paul Cartwright as the company's Data Protection Officer, a role responsible for compliance with UK data protection regulations [PERPLEXITY SONAR PRO BRIEF].
Partially corroborated -- Company details confirmed via Companies House; product and operational claims are from the company's own website and policies, with limited independent corroboration.
Under the Hood
Reported and inferred Vivere's product suite is a direct-to-consumer bundle of diagnostics and therapeutics, anchored by a high-resolution gut microbiome test and a pharmaceutical-grade NAD+ injection pen. The company's primary offering is an at-home test kit that uses shotgun metagenomic sequencing, a method that provides more detailed genetic analysis of gut bacteria than the 16S rRNA sequencing common in earlier consumer tests [viverelife.co.uk]. This core diagnostic is packaged with a 45-minute consultation with a nutritionist and a personalized online dashboard that delivers AI-powered nutrition and lifestyle recommendations, creating a closed-loop service priced at £263.99 (promotional) for a bundle the company values at over £420 [viverelife.co.uk]. The second pillar is a longevity-focused therapeutic: a self-administered NAD+ injection pen, sold with refill kits, which is marketed for cellular repair and energy [viverelife.co.uk]. A wellness e-commerce shop rounds out the commercial model, selling both Vivere-branded and third-party supplements like Garden of Life probiotics [viverelife.co.uk].
The technology wedge appears to be the integration of a higher-fidelity diagnostic with a personalized software layer and a specific therapeutic intervention. The AI component, referenced in marketing materials, is likely applied to generate individualized health insights from the sequencing data, though the specific algorithms, training data, or software stack are not detailed publicly [viverelife.co.uk]. The company's operational focus is strictly domestic; all services are restricted to users aged 18 and over with a UK shipping address, indicating a tailored logistics and regulatory approach for a single market [viverelife.co.uk]. The product pages and terms of service show updates through August 2026, suggesting active iteration on packaging, pricing, and compliance framing [viverelife.co.uk].
Partially corroborated -- Product details and pricing are confirmed from the company website. The AI and sequencing technology claims are described by the company but lack independent technical verification.
Market Research
Open sources
The consumer health and longevity market is shifting from generalized wellness advice to data-driven, personalized interventions, a transition that creates openings for startups offering specific, measurable biomarkers. For Vivere Life, the relevant market is the intersection of at-home diagnostics, the gut health category, and the emerging direct-to-consumer longevity therapeutics space. This analysis relies on analogous market reports and observable demand drivers, as the company itself has not published proprietary market sizing.
The total addressable market for at-home health testing is substantial and growing. According to a Grand View Research report, the global at-home testing market size was valued at $20.7 billion in 2023 and is projected to expand at a compound annual growth rate of 7.9% from 2024 to 2030 [Grand View Research, 2024]. Within this, the gut microbiome testing segment is a key driver. The broader consumer interest in gut health is well-documented, with the global probiotics market alone estimated at $61.9 billion in 2022 and forecast to reach $95.9 billion by 2030 [Allied Market Research, 2023]. These figures, while not specific to the UK or to Vivere's premium niche, illustrate the scale of the underlying consumer behavior the company is targeting.
Demand is propelled by several converging tailwinds. The post-pandemic acceleration of telehealth and DTC health models has normalized remote testing. Concurrently, a growing body of peer-reviewed research continues to link gut microbiome composition to a wide range of health outcomes, from metabolic health to mental well-being, fueling consumer curiosity. The 'biohacking' and longevity movements, popularized through podcasts and social media, have created a cohort of consumers willing to invest in advanced, proactive health measures beyond standard supplements. This demographic is typically less price-sensitive and seeks products with a perceived scientific edge, such as shotgun metagenomic sequencing over cheaper 16S rRNA methods.
Key adjacent and substitute markets present both opportunity and risk. The broader nutraceutical and supplement industry is a direct substitute for some of Vivere's product suggestions, though the company attempts to integrate testing to justify specific recommendations. The clinical diagnostics market represents a potential future channel but is currently a boundary; consumer tests like Vivere's are not intended for medical diagnosis. Regulatory forces are a critical consideration, particularly in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees medical devices, and while at-home wellness tests currently occupy a less stringent category, any claims linking test results to disease prevention or treatment could attract scrutiny. The company's sale of an injectable NAD+ product also operates in a regulatory gray area between a wellness supplement and a pharmaceutical, requiring careful compliance with safety and marketing standards.
Partially corroborated -- Market sizing is based on analogous, third-party industry reports for broader categories; no company-specific or niche-market sizing is publicly confirmed.
Competition and Substitutes
Reported and inferred
Vivere Life enters a crowded and fragmented wellness market by bundling high-resolution gut microbiome analysis with a pharmaceutical-grade longevity product, a combination not yet standardized by any single UK incumbent.
The competitive analysis proceeds as prose, mapping the landscape from public sources.
The competitive map for consumer health testing and biohacking in the UK is divided into three primary segments, each with distinct players. In the gut microbiome testing space, companies like Zoe (US/UK) and Atlas Biomed (UK) have established strong brand recognition and scientific advisory boards, offering sequencing and dietary advice. The NAD+ and longevity supplement segment is served by a range of online pharmacies, specialized clinics, and direct-to-consumer brands like Elevant (selling NMN) and AgelessRx (US-based, offering prescription compounds). Finally, the general wellness and supplement e-commerce segment is dominated by large retailers (Holland & Barrett, Boots) and curated marketplaces. Vivere's positioning attempts to bridge the first two segments, offering the test and the therapeutic intervention under one brand.
Vivere's current, narrow edge appears to be its specific product bundling and regulatory positioning. The company's use of shotgun metagenomic sequencing, while not unique, is a higher-resolution method than the 16S rRNA sequencing used by some earlier entrants, which could be marketed as a technical differentiator [viverelife.co.uk]. More notably, its sale of a "pharmaceutical-grade" NAD+ injection pen positions it in a more regulated product category than oral supplements, potentially creating a perception of efficacy and safety. This edge is highly perishable, however. It depends entirely on maintaining compliant UK manufacturing and distribution, and any established player with deeper clinical partnerships or a broader therapeutic license could replicate or surpass this offering quickly. The company's data asset from test results is nascent and likely not yet at a scale to drive a durable AI advantage.
The company is most exposed on two fronts: brand scale and capital. In the gut health segment, Zoe has secured significant venture funding and built a substantial community, making customer acquisition costly for a new entrant. In the longevity product space, Vivere lacks the clinical validation or published research partnerships that lend credibility to more established brands. Furthermore, its UK-only shipping restriction, while a focused wedge, also caps its total addressable market and makes it vulnerable to a scaled international player deciding to launch a similar bundled service in the region. The direct-to-consumer channel it relies on is expensive and competitive, with no evident owned community or proprietary distribution.
The most plausible 18-month scenario sees further fragmentation rather than consolidation. A winner in this niche would be a company that successfully transitions from a DTC product brand to a trusted provider with some form of clinical or employer partnership, validating its health claims beyond customer testimonials. A loser would be any pure-play DTC operator, including Vivere in its current form, that fails to move beyond promotional pricing and review-driven sales, as customer lifetime value may prove insufficient to cover rising customer acquisition costs in a noisy market. The outcome likely hinges on whether any player in this bundle-first category can demonstrate measurable, repeatable health outcomes that justify the premium price point to a broader audience.
Partially corroborated -- Landscape analysis is inferred from public market descriptions; specific competitor intelligence and funding details are not sourced for direct comparison.
Opportunity
Open sources The opportunity for Vivere Life is to become the UK's dominant integrated platform for personalized longevity interventions, capturing a premium segment of the health-conscious consumer market by bundling advanced diagnostics with targeted therapeutics.
The headline opportunity is to establish a category-defining, direct-to-consumer health brand that moves beyond single-point testing to become a trusted, recurring source for validated longevity protocols. This outcome is reachable because the company's initial wedge combines two high-intent, high-value services: deep, AI-interpreted gut microbiome analysis and pharmaceutical-grade NAD+ therapy. The integration of a diagnostic test with a subsequent therapeutic product creates a natural, high-margin cross-sell path within a single customer journey, a structure that is cited as core to its current offering [viverelife.co.uk]. The restriction to the UK market, while limiting geographic scope, allows for focused regulatory navigation and brand building in a single, affluent healthcare jurisdiction, making a path to regional dominance more plausible than a fragmented global launch.
Growth from this initial position could follow several concrete paths, each hinging on specific, near-term catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Vertical Integration into Supplementation | Vivere uses gut test data to drive automated, high-margin sales of its own branded supplement lines, moving beyond third-party curation. | Launch of proprietary, data-informed supplement formulations. | The company already operates a wellness shop and provides personalized product suggestions based on test results, establishing the commercial and data infrastructure for this move [viverelife.co.uk]. |
| B2B2C Partnership Model | The testing and recommendation platform is white-labeled or offered as a benefit through corporate wellness programs, private clinics, or fitness chains. | Securing a pilot partnership with a UK-based wellness provider or employer. | The product's at-home, digital-first delivery model and AI-powered dashboard are inherently scalable and could be repackaged for B2B channels without significant product rework. |
| Portfolio Expansion via New Biomarkers | The company layers additional at-home tests (e.g., epigenetics, advanced metabolic panels) onto its existing customer base and dashboard. | Introduction of a second proprietary test kit. | Success with the initial gut test creates a captive audience for additional diagnostic products, leveraging the same logistics, brand trust, and AI interpretation layer. |
Compounding for Vivere would manifest as a data-driven personalization flywheel. Each gut microbiome test result enriches the proprietary dataset that powers its AI recommendation engine. As the dataset grows, the platform's suggestions for nutrition, lifestyle, and supplemental interventions become more precise and, theoretically, more effective. Demonstrated efficacy, even anecdotally through customer reviews, drives higher customer lifetime value through repeat purchases of NAD+ refills or new tests, and increases referral rates. Early signals of this loop are present in the form of user-generated reviews on platforms like Trustpilot, which serve as social proof and a potential source of qualitative data on outcomes [Trustpilot, March 2026]. This creates a potential data moat: the company's recommendations become uniquely tailored to its UK customer base and their specific microbiomes, a asset difficult for a new entrant to replicate quickly.
The size of the win can be framed by looking at comparable, though more mature, personalized health companies. For example, Zoe, a UK/US-based gut microbiome and nutrition program, has reportedly reached hundreds of thousands of users and secured significant venture funding, indicating the scale of consumer demand and investor appetite for this category. While a direct valuation comparison is not possible without Vivere's financials, the precedent suggests that a successful, vertically-integrated player in the personalized longevity space can achieve a valuation in the high hundreds of millions to billions of dollars (scenario, not a forecast). For Vivere, executing on the vertical integration or portfolio expansion scenarios to capture a meaningful share of the UK's premium wellness market could position it as a compelling acquisition target for larger consumer health or pharmaceutical companies seeking direct consumer access and proprietary health data.
Partially corroborated -- Product and market positioning are confirmed by the company's website and third-party review platforms. Growth scenarios and market comps are extrapolated from the company's current model and analogous players, as no public partnership or expansion announcements exist.
Sources
Open sources
[Companies House] Vivere Life Limited - Company number 15899819 | https://find-and-update.company-information.service.gov.uk/company/15899819
[viverelife.co.uk] Vivere: UK's Leader in Gut Testing, NAD+ Therapy & Biohacking | https://www.viverelife.co.uk/
[Trustpilot, February 2026] Vivere Reviews | Read Customer Service Reviews of viverelife.co.uk | https://uk.trustpilot.com/review/viverelife.co.uk
[Trustpilot, March 2026] Vivere Reviews | Read Customer Service Reviews of viverelife.co.uk | https://uk.trustpilot.com/review/viverelife.co.uk
[Grand View Research, 2024] At-Home Testing Market Size, Share & Trends Analysis Report | URL not provided in structured facts.
[Allied Market Research, 2023] Probiotics Market Size, Share, Competitive Landscape and Trend Analysis Report | URL not provided in structured facts.
[PERPLEXITY SONAR PRO BRIEF] Web-grounded research brief on Vivere Life Limited | URL not provided in structured facts.
Articles about Vivere Life Limited
- Vivere Life's £264 Gut Test Puts Shotgun Sequencing Into UK Homes — The Nottingham startup combines high-resolution microbiome analysis with AI recommendations and NAD+ pens, betting on a direct-to-consumer longevity market.